Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening
Smoking Cessation
About this trial
This is an interventional treatment trial for Smoking Cessation focused on measuring Patients, Underserved, Early Detection of Cancer, Lung Cancer, Nicotine Replacement Products, Incentives, Behavioral Economics, Smoking Cessation, Nicotine Dependence
Eligibility Criteria
Inclusion Criteria:
- Current smoker (≥ 1 cigarettes per day, not including e-cigarettes)
- Has a low-dose computed tomography (LDCT) scan ordered by their physician
- Underserved, defined as one or more of the following: (a) Black, (b) Hispanic, (c) rural residence, or (d) low socioeconomic status (Defined as one or both of: high-school education or less, or household income <200% of the federal poverty line)
- Able to receive study invitation and screening, by virtue of showing up to a radiology location affiliated with a participating health system for the LDCT, or having a valid email address or telephone number on file with the health system
- Access to a cell phone with text messaging or the internet
- Aged 18 years or older
Exclusion Criteria:
- No cell phone
Sites / Locations
- Kaiser Permanente Southern CaliforniaRecruiting
- Henry Ford Health SystemRecruiting
- GeisingerRecruiting
- University of PennsylvaniaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
No Intervention
Active Comparator
Active Comparator
Active Comparator
Basic Usual Care
Enhanced Usual Care
Enhanced Usual Care plus Financial Incentives
Enhanced Usual Care plus Financial Incentives plus Mobile Health Application
Participants receive the usual care approach, Ask-Advise-Refer (AAR), which is a standard approach in which non-study clinicians ask smokers about their desire to quit smoking, advise them to quit, and provide informational resources such as hotlines, specialized clinics, or smoking cessation classes.
Participants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians.
Participants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.
Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the "future is now" between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner.